Clinical Trial

A Phase 2 Study to Describe the Safety and Immunogenicity of Respiratory Syncytial Virus Vaccine IN006 in Healthy Participants Aged 60 Years and Older

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The study will evaluate the safety, tolerability, and immunogenicity of 2 dose levels of IN006 in healthy participants who aged at 60 years or older; of a revaccination of IN006 given 12 months or 24 months after the initial vaccination.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-08-11; most recent amendment 2025-09-08.
Status change: Recruiting → Active, Not Recruiting 2025-09-08
Trial Details
NCT Number NCT07128121
Lead Sponsor Shenzhen Shenxin Biotechnology Co., Ltd
Conditions Respiratory Syncytial Virus (RSV) Infection
Enrollment 500 participants
Start Date 2025-08-13
Primary Completion 2029-10 (estimated)
Study Completion 2029-10 (estimated)
Updated on ClinicalTrials.gov 2025-09-09